DLF

Well placed to ride headwinds

DLF reported Revenue/EBITDA/APAT at Rs 16.1/4.6/3.3 bn, ~2x/3.7x/3.5x our estimates, on back of revenue recognition from Camellias (Rs 7.5bn). Presales rebounded to Rs 8.5bn vs Rs 1.5bn QoQ. Excluding the sale of AMEX commercial campus, sales bookings stood at Rs 4.7bn, a decline of 35% YoY. While office portfolio remains robust with +98% collections, retail is inching towards recovery with footfall at 35-40% of pre-pandemic level. Gradual recovery in presales, strong launch pipeline and REIT plans for DCCDL augur well for re-rating. We maintain BUY on DLF, with unchanged TP of Rs 219, given healthy balance sheet and change our FY21/FY22/FY23 EPS estimates by 3.5/-3.9/-16.3% to front load revenue from Camellias project.

- 2QFY21 highlights: DLF registered consolidated revenue at Rs 16.1bn, -6.2%/~3x YoY/QoQ and ~2x our estimates, as it started to recognize revenue from Camellias (Rs 7.5bn) in 2QFY21. EBIDTA margins also improved to 28.4% (20.4/0.3% 2QFY20/1QFY21), on the Camellias revenue recognition. Finance costs declined by 46/5% YoY/QoQ. Adjusting the provision (Rs 962mn) made against interest levied on overdue receivables, APAT came in at Rs 3.3bn, a rise of 9% YoY and ~3.5x our estimates.
- Presales recovering; launches planned across categories: DLF reported sales booking at Rs 8.5bn, rise of 18% YoY. However, excluding the AMEX commercial sales, bookings declined by 35% YoY to Rs 4.7bn. Of Rs 66bn completed inventory, Rs 44bn is from Camellia, which we believe would see back-ended recovery, given the large ticket size. DLF is planning to launch 10 msf of mid-income housing from H1FY22 and expand commercial portfolio with the launch of Hines JV and new developments in DLF 5.
- Balance sheet position comfortable: Consolidated net debt remained stable at Rs 52bn at the end of quarter (vs Rs 52bn on Jun-20 end), with net D/E at 0.15x. Net debt is likely to remain at the same level given the planned residential launches which will largely self-finance. The company also brought down interest cost from 9.7% in 1QFY21 to 9.1% during the quarter. DLF generated positive operating cashflow of Rs 2bn during 1HFY21.

Financial summary

YE March (Rs mn)	2Q FY21	2Q FY20	YoY (%)	1Q FY21	QoQ (%)	FY20	FY21E	FY22E	FY23E
Net Sales	16,098	17,155	(6.2)	5,486	193.4	60,828	47,446	49,343	43,422
EBITDA	4,631	3,504	32.2	17	26,669.9	11,350	11,746	12,492	11,371
APAT	3,284	3,025	8.6	(707)	NA	11,106	8,045	10,557	11,687
Diluted EPS (Rs)	1.3	1.2	8.6	(0.3)	NA	4.5	3.2	4.3	4.7
P/E (x)						35.3	48.7	37.1	33.5
EV / EBITDA (x)						38.0	37.4	33.5	38.4
RoE (%)						3.3	2.3	3.0	3.2

Estimate change summary

Rs mn	FY21			FY22			FY23		
KS IIII	New	Old	% diff	New	Old	% diff	New	Old	% diff
Revenue	47,446	40,289	17.8	49,343	36,260	36.1	43,422	41,699	4.1
EBITDA	11,746	7,273	61.5	12,492	6,428	94.3	11,371	7,466	52.3
Margin (%)	24.8	18.1	670.6	25.3	17.7	758.8	26.2	17.9	828.3
APAT	8,045	7,774	3.5	10,557	10,990	(3.9)	11,687	13,963	(16.3)

Source: Company, HSIE Research; Consolidated Financials



BUY CMP (as on 30 Oct 2020) Rs 158 Target Price Rs 219 NIFTY 11,642 KEY OLD CHANGES DUV

Rating	BUY	BUY
Price Target	Rs 219	Rs 219
EPS Change %	FY21E	FY22E
El 5 Change %	3.5	-3.9

KEY STOCK DATA

Bloomberg code	DLFU IN
Biooniberg code	DLFUIN
No. of Shares (mn)	2,475
MCap (Rs bn) / (\$ mn)	392/5,255
6m avg traded value (Rs mn)	1,935
52 Week high / low	Rs 267/115

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	13.0	7.8	(12.8)
Relative (%)	8.0	(9.7)	(11.7)

SHAREHOLDING PATTERN (%)

	Jun-20	Sep-20
Promoters	74.95	74.95
FIs & Local MFs	1.76	1.65
FPIs	18.54	18.33
Public & Others	4.75	5.07
Pledged Shares	-	-
Source: BSE		

Parikshit D Kandpal, CFA

parikshitd.kandpal@hdfcsec.com +91-22-6171-7317

Chintan Parikh

chintan.parikh@hdfcsec.com +91-22-6171-7330

Rohan Rustagi

rohan.rustagi@hdfcsec.com +91-22-6171-7355



HSIE Results Daily

Disclosure:

Authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issue(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. **does not have** any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate **does not have** any material conflict of interest.

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

HDFC securities Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013 Board: +91-22-6171-7330 www.hdfcsec.com